Dangas GD, Tijssen JGP, Wöhrle J, et al. - Experts randomized 1,644 individuals without an established indication for oral anticoagulation following successful transcatheter aortic valve replacement (TAVR) to receive rivaroxaban at a dose of 10 mg daily (rivaroxaban group) or aspirin at a dose of 75 to 100 mg daily (antiplatelet group) in order to determine whether the direct factor Xa inhibitor rivaroxaban could prevent thromboembolic events following TAVR. It was found that in people without an authorized implication for oral anticoagulation following successful TAVR, compared with an antiplatelet-based strategy, a treatment approach including rivaroxaban at a dose of 10 mg daily was related to a greater risk of death or thromboembolic complications and bleeding.